Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 2/2013

01-06-2013 | case report

Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody

Authors: Cathrin Skrabs, Christian Sillaber, Ana-Iris Schiefer, Ingrid Simonitsch-Klupp, Thomas Staudinger, Monique Putman, Werner Rabitsch, Ulrich Jaeger

Published in: memo - Magazine of European Medical Oncology | Issue 2/2013

Login to get access

Abstract

Background

Patients with follicular lymphoma ineligible for standard treatment with the anti-CD20 antibody rituximab represent a considerable challenge as they require alternative therapeutic approaches.

Patient and methods

We describe a patient who experienced a severe episode of serum sickness. Antichimeric antibodies against rituximab were verified in an early stage of disease, rendering further use of the drug impossible. After five treatment lines he developed progressive follicular lymphoma with skin involvement, which was treated with lenalidomide monotherapy.

Results

Six cycles of lenalidomide monotherapy (25 mg orally for 21 days, 1 week off) led to a very good partial response rendering the patient eligible for autologous stem cell transplantation. Data on efficacy of lenalidomide in follicular lymphoma are reviewed.

Conclusion

As shown here, single-agent lenalidomide represent a therapeutic option for pretreated patients with follicular lymphoma ineligible for rituximab.
Literature
1.
The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–18.
2.
Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2007;216–25.
3.
4.
Dreyling M, Ghielmini M, Marcus R, et al. ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 (Suppl 6):vi59–63.PubMedCrossRef
5.
O’Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676–84.PubMedCrossRef
6.
Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010;116:106–14.PubMed
7.
Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol. 2009;27:5404–9.PubMedCrossRef
8.
Rituxan (Rituximab) injection [prescribing information]: San Francisco: Genentech, Inc.; 2011.
9.
DeMonaco NA, Jacobs SA. Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan. Clin Nucl Med. 2007;32:933–4.PubMedCrossRef
10.
Disperati P, Hicks LK, Buckstein R. Rituximab-induced serum sickness in a patient with follicular lymphoma. Leuk Lymphoma. 2007;48:1633–5.PubMedCrossRef
11.
Goto S, Goto H, Tanoshima R, et al. Serum sickness with an elevated level of human antichimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol. 2009;89:305–9.PubMedCrossRef
12.
Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumor activity of rituximab in vivo. Br J Haematol. 2008;140:36–45.PubMed
13.
Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41–4.PubMedCrossRef
14.
Fowler N, Hagemeister F, Mclaughlin P, et al. Lenalidomide plus rituximab is a highly effective and well-tolerated biologic therapy in untreated indolent B cell non-Hodgkins lymphoma. Abstract 137, 11th International Conference on Malignant Lymphoma 15–18 June 2011, Lugano (Switzerland), Ann Oncol. 2011;22(Suppl 4):iv128–9.
15.
Dutia M, Deroock I, Reed-Pease C, et al. Lenalidomide plus rituximab leads to a high rate of durable responses in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma. Abstract 306, 11th International Conference on Malignant Lymphoma 15–18 June 2011, Lugano (Switzerland), Ann Oncol. 2011;22(Suppl 4):iv183–9.
16.
Ahmadi T, Chong EA, Gordon A, et al. Phase II trial of lenalidomide—dexamethasone—rituximab in relapsed or refractory indolent B-Cell or mantle cell lymphomas resistant to rituximab. ASH Annual Meeting Abstracts. 2010;116:3962.
17.
Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4952–7.PubMedCrossRef
18.
Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622–7.PubMedCrossRef
19.
Chanan-Khan A, Miller KC, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011;117:2127–35.PubMedCrossRef
Metadata
Title
Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody
Authors
Cathrin Skrabs
Christian Sillaber
Ana-Iris Schiefer
Ingrid Simonitsch-Klupp
Thomas Staudinger
Monique Putman
Werner Rabitsch
Ulrich Jaeger
Publication date
01-06-2013
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2013
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0089-5

Other articles of this Issue 2/2013

memo - Magazine of European Medical Oncology 2/2013 Go to the issue

short review

Optimal surveillance strategy of localised testicular non-germ cell sex-cord stromal tumours

special report

Single-agent bevacizumab as maintenance therapy in metastatic colorectal cancer: how long do we have to continue?

review

Therapy with JAK 1/2 inhibitors for myelofibrosis

short review

The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network


review

Biomolecular basis of the role of chronic psychological stress hormone ‘‘glucocorticoid’’ in alteration of cellular immunity during cancer

short review

The role of maintenance strategies in lymphoma and CLL

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits